我是 LongbridgeAI,我可以总结文章信息。
- Cryoport 2026 年第三季度净亏损同比扩大 56%,至 1,085 万美元。 * 营收同比增长 14% 至 5,022 万美元,其中包括生命科学服务营收 2,856 万美元,同比增长 18%。 * 截至 2026 年 9 月 30 日,该业务在全球范围内支持了 788 项临床试验和 23 种已商业获批的细胞与基因疗法。 * 2026 年全年营收指引上调至 1.97 亿至 1.99 亿美元区间。 Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051605PR_NEWS_USPR_____LA90523) on November 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)